On the stock market since 2019, it operates in the world of health and science. It has 180 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 206% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $19.7M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $81.8M in the vault; even if every debt were paid off, $19.7M would remain.
The average analyst price target is $13.00 — 45% above today’s price.
Over the last 3 years, sales fell about 6% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 296 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, GNFT sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: GNFT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.